Researchers from Zymeworks Inc. recently reported preclinical data for ZW-220, an antibody-drug conjugate (ADC) consisting of humanized IgG1 monoclonal antibody targeting sodium-dependent phosphate transport protein 2B (SLC34A2, NaPi2b) conjugated to a topoisomerase I inhibitor, being developed for the treatment of cancer.
Antibody-drug conjugates (ADCs) combine monoclonal antibody-targeting capabilities with the cytotoxic effect of conjugated drug payloads. However, there is a need for enhanced strategies to overcome restricted therapeutic window or unacceptable off-target effects.
Ideaya Biosciences Inc. has exercised its option for an exclusive worldwide license for Biocytogen Pharmaceuticals (Beijing) Co. Ltd.’s B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate (ADC), BCG-034 (IDE-034), and nominated it as a development candidate.
Anti-HER2 antibody-drug conjugates (ADCs) have proven effective in multiple tumor types. However, between 64% and 85% of HER2+ breast and gastric cancer patients retain HER2 expression after treatment with trastuzumab deruxtecan (T-Dxd), which includes a topoisomerase I inhibitor payload.
Duality Biologics Ltd. presented preclinical data on DB-1419, a potentially first-in-class bispecific antibody-drug conjugate (ADC) consisting of a humanized antibody targeting B7-H3 and PD-L1 conjugated to a DNA topoisomerase I inhibitor under development for the treatment of cancer.
Celltrion Inc. posted preclinical study results of two new antibody-drug conjugate (ADC) candidates – CT-P70 and CT-P71 – at the World ADC 2024 conference in San Diego Nov. 6, with plans to move the assets into clinical trials. Poster presentations of both ADC candidates “drew significant attention from the attendees” at the oncology meeting, Incheon, South Korea-based Celltrion said, while highlighting its efforts to transition from a biosimilar maker to a novel therapy developer.
Celltrion Inc. posted preclinical study results of two new antibody-drug conjugate (ADC) candidates – CT-P70 and CT-P71 – at the World ADC 2024 conference in San Diego Nov. 6, with plans to move the assets into clinical trials. Poster presentations of both ADC candidates “drew significant attention from the attendees” at the oncology meeting, Incheon, South Korea-based Celltrion said, while highlighting its efforts to transition from a biosimilar maker to a novel therapy developer.
Researchers from Eli Lilly & Co. presented the discovery and preclinical characterization of a novel protein tyrosine kinase 7 (PTK7)-targeting antibody-drug conjugate (ADC), LY-4175408, being developed for the treatment of cancer.
Iksuda Therapeutics Ltd. disclosed the design of a novel, effective and safe antibody-drug conjugate (ADC), IKS-012, for the potential treatment of folate receptor α (FRα)-positive cancers.
RSS
